3D Tumor Culture Models for Drug Resistance Screening and Precision Oncology

Abstract

The persistent high attrition rate of novel oncological therapeutics in clinical trials highlights the profound limitations of traditional two-dimensional cell culture paradigms. To address the fundamental disconnect between preclinical in vitro findings and actual patient outcomes, three-dimensional tumor culture models have emerged as a highly sophisticated alternative. This comprehensive paper explores the architectural, biological, and mechanical intricacies of three-dimensional tumor models, encompassing spheroids, patient-derived organoids, and microfluidic organ-on-a-chip technologies. By faithfully recapitulating the complex spatial heterogeneity, hypoxia gradients, and extracellular matrix interactions inherent to human solid tumors, these advanced methodologies provide unparalleled insights into intrinsic and acquired drug resistance mechanisms. Furthermore, the integration of these models into high-throughput screening platforms offers a transformative approach to precision oncology, enabling personalized therapeutic regimens based on the functional profiling of patient-specific tumor tissues. Through an exhaustive examination of current methodologies, analytical techniques, and clinical translations, this paper delineates the substantial advantages and prevailing challenges of implementing three-dimensional cultures in mainstream pharmaceutical development. The synthesis of robust extracellular matrices, the simulation of interstitial fluid dynamics, and the precise quantification of heterogeneous drug penetration are critically analyzed to project the future trajectory of preclinical cancer research.